DE-109 FDA Approval Status
FDA Approved: No
Brand name: DE-109
Generic name: sirolimus
Dosage form: Intravitreal Injection
Company: Santen Pharmaceutical Co., Ltd.
Treatment for: Uveitis
DE-109 (sirolimus) is a locally-administered, non-steroidal immunoregulator in development for the treatment of non-infectious uveitis of the posterior segment (NIU-PS).
Development timeline for DE-109
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
